Suzan Diane Scharr, RN, BSN, IBCLC, CCCE Registered Nurse - Lactation Consultant Medicare: Not Enrolled in Medicare Practice Location: 15 Marla Ln, East Falmouth, MA 02536 Phone: 508-524-3651 |
Victoria M Klein, REGISTERED NURSE Registered Nurse - Community Health Medicare: Not Enrolled in Medicare Practice Location: 609 Sandwich Rd, East Falmouth, MA 02536 Phone: 774-521-6280 |
Bridgette Lyndsey Medeiros, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 245 Carriage Shop Rd, East Falmouth, MA 02536 Phone: 508-654-4331 |
Michael George Pringle, RN Registered Nurse - Emergency Medicare: Not Enrolled in Medicare Practice Location: 31 Mill Farm Way, East Falmouth, MA 02536 Phone: 774-602-0597 |
Cecilia Jane King, Registered Nurse - Medical-Surgical Medicare: Not Enrolled in Medicare Practice Location: 18 Pine Cone Ln, East Falmouth, MA 02536 Phone: 508-524-0528 |
Mrs. Chelsea Lynn Cintron, RN Registered Nurse - Home Health Medicare: Not Enrolled in Medicare Practice Location: 307 E Falmouth Hwy, East Falmouth, MA 02536 Phone: 774-228-1524 |
Kelly Noelle Palmer, NP Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 106 Jamie Ln, East Falmouth, MA 02536 Phone: 207-357-4693 |
News Archive
Drexel University researchers are one step closer to offering a new treatment for the millions of patients who suffer from slow-healing, chronic wounds.
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) recently accepted the filing for review of the New Drug Application (NDA) for asenapine, a fast-dissolving, sublingual tablet.
Researchers from the University of Alabama at Birmingham Department of Occupational Therapy have published new findings that suggest spending 20 minutes in an urban park will make someone happier regardless of whether they are engaging in exercise or not during the visit.
A team led by the Department of Energy's Oak Ridge National Laboratory has identified a novel microbial process that can break down toxic methylmercury in the environment, a fundamental scientific discovery that could potentially reduce mercury toxicity levels and support health and risk assessments.
Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.
› Verified 2 days ago